Moxidectin FDA Approval History
FDA Approved: Yes (First approved June 13, 2018)
Generic name: moxidectin
Dosage form: Tablets
Company: Medicines Development for Global Health
Treatment for: Onchocerciasis, River Blindness
Last updated by Judith Stewart, BPharm on May 12, 2025.
Moxidectin is an anthelmintic indicated for the treatment of onchocerciasis due to Onchocerca volvulus in adults and pediatric patients aged 4 years and older and weighing at least 13 kg.
Development timeline for moxidectin
| Date | Article |
|---|---|
| Feb 20, 2025 | Approval U.S. FDA Expands Indication for Moxidectin to Treat River Blindness in Children as Young as Four |
| Jun 13, 2018 | Approval FDA Approves Moxidectin for the Treatment of River Blindness |
See also
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.